Summary
Dexamethasone (20 mg) or its equivalent in combination with 5-HT3 antagonists appears to be the gold-standard dose for antiemetic prophylaxis. Additional to concerns about the use of corticosteroids with respect to enhanced tumour growth or impaired killing of the tumour cells, there is evidence that high-dosage dexamethasone impairs the control of delayed nausea and emesis, whereas lower doses appear more beneficial. To come closer to the most adequate dose, we started a prospective, single-blind, randomized trial investigating additional dosage of 8 or 20 mg dexamethasone to tropisetron (Navoban), a 5-HT3 receptor antagonist, in cis-platinum-containing chemotherapy. After an interim analysis of 121 courses of chemotherapy in 69 patients, we have been unable to detect major differences between both treatment alternatives. High-dose dexamethasone (20 mg) had no advantage over medium-dose dexamethasone with respect to objective and subjective parameters of acute and delayed nausea and vomiting. In relation to concerns about the use of corticosteroids in non-haematological cancer chemotherapy, we suggest that 8 mg or its equivalent should be used in combination with 5-HT3 antagonists until further research proves otherwise.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Aapro, M. S. & Alberts, D. S. (1981). High-dose dexamethasone for prevention of cisplatin-induced vomiting. Cancer Chemother Pharmacol 7: 11–14.
Balzon, J-C & Zorzano-Estrade, C. (1987). Utilisation de l’alizapride (Plitican) seul ou associé à une forte dose de corticoides dans les troubles digestifs induits par le cisplatine. Comptes Rendus Ther Pharmacol Clin 52: 13–19.
Campora, E., Giudici, S., Merlini L Rubagotti, A. & Rosso, R. (1994). Ondansetron and dexamethasone versus standard combination antiemetic therapy. Am J Clin Oncol 17: 522–526.
Carmichael, J., Bessel, E. M., Harris, A. L., Hucheon, A. W., Dawes, PJDK & Daniels, S. (1994). Comparison of granisetrone alone and granisetron plus dexamethasone in the prophylaxis of cytotoxic-induced emesis. Br J Cancer 70: 1161–1164.
de Haes, JCJM, van Knippenberg, F. C. E. & Neijt, J. P. (1990). Measuring psychological and physical distress in cancer patients: structure and application of the Rotterdam symptom checklist. Br J Cancer 62: 1034–1038.
Fredrikson, M., Hursti, T., Fürst, C. J., Steineck, G., Börjeson, S., Wikblom, M. & Peterson, C. (1992). Nausea in cancer chemotherapy is inversely related to urinary cortisol excretion. Br J Cancer 65: 779–780.
Haid, M. (1981). teroid antiemesis may be harmful. N Engl J Med 304: 1237
Hawthorn, J. & Cunningham, D. (1990). Dexamethasone can potentiate the antiemetic action of a 5-HT3-receptor antagonist on cyclophosphamide induced vomiting in the ferret. Br J Cancer 61: 56–60.
Hursti, T. J., Fredrikson, M., Steineck, G., Börjeson, S., Fürst, C. J. & Peterson, C. (1993). Endogenous cortisol exerts antiemetic effect similar to that of exogenous corticosteroids. Br J Cancer 68: 112–114.
Livera, P., Trojano, M. & Simone, I. (1985). Acute changes in blood CSF barrier permselectivity to serum proteins after intrathecal methotrexat and CNS irradiation. J Neurol 231: 336–339.
Münstedt, K., Milch, W., Blauth-Eckmeyer, E., Spänle, A. & Vahrson, H. (1995). Prevention of cisplatinum-induced delayed emesis and nausea. Onkologie 18: 23–26.
Peterson, C., Hursti, T. J., Börjeson, S., Avall-Lundquist, E., Fredrickson, M., Fürst, C. J., Lomberg, H. & Steineck, G. (1996). Single high-dose dexamethasone improves the effect of ondansetron on acute chemotherapy-induced nausea and vomiting but impairs the control of delayed symptoms. Support Care Cancer 4: 440–446.
Powell, C. B., Mutch, D. G., Kao, M-S, Wen-Yun, J., Perry, D. L., Westphale, E. & Collins, J. L. (1990). Dexamethasone used as an antiemetic in chemotherapy protocols inhibits natural cytotoxic (NC) cell activity. Cancer 65: 466–472.
Sagar, S. (1991). The current role of anti-emetic drugs in oncology: a recent revolution in patients’ symptom control. Cancer Treat Rev 18: 95–135.
Sherlock, M. & Hartmann, W. H. (1962). Adrenal steroids and the pattern of metastases of breast cancer. JAMA 181: 313–317.
Stephens, S. H., Silvey, V. L. & Wheeler, R. H. (1990). A randomized, double-blind comparison of the antiemetic effect of metoclopramide and lorazepam with or without dexamethasone in patients receiving high-dose cisplatin. Cancer 66: 443–446.
Young, S. N. (1981). Mechanism of decline in rat brain 5-hydroxytryptamine after induction of liver tryptophan pyrrolase by hydrocortisone: roles of tryptophan catabolism and kynurenine synthesis. Br J Pharmacol 74: 695
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Münstedt, K., Müller, H., Blauth-Eckmeyer, E. et al. Role of dexamethasone dosage in combination with 5-HT3 antagonists for prophylaxis of acute chemotherapy-induced nausea and vomiting. Br J Cancer 79, 637–639 (1999). https://doi.org/10.1038/sj.bjc.6690100
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6690100
Keywords
This article is cited by
-
Anticipatory nausea in animal models: a review of potential novel therapeutic treatments
Experimental Brain Research (2014)
-
Treatment of Chemotherapy-Induced Nausea and Vomiting
Journal of Gastrointestinal Cancer (2012)
-
Gastroparesis secondary to a demyelinating disease: a case series
BMC Gastroenterology (2007)